FDA
-
-
-
-
-
-
-
Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
ASSERTIO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Dollar General, Estee, VNET, and Assertio and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition
-
-
-
-
-
-
-
Assertio Therapeutics (ASRT) Granted FDA Orange Book Listing for New Sympazan Oral Film Patent
-
-
-
-
-
-
-
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRI
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

